BD said Wednesday CFO Chris DelOrefice will leave the company Dec. 5 to pursue another professional opportunity, and it is conducting a search for a permanent successor.
DelOrefice, who will join Ulta Beauty as CFO, informed BD of his intention to resign on Oct. 9, the company said in a regulatory filing. He joined BD in 2021 from Johnson & Johnson, where he spent nearly two decades.
Vitor Roque, senior vice president of finance, business units and corporate financial planning and analysis, will become BD’s interim CFO when DelOrefice departs and will serve in the role until a permanent successor is named, the company said. Roque will work with DelOrefice and BD’s leadership teams to facilitate the transition.
Roque has held a range of finance leadership roles during two decades with the company and has supported key acquisitions, BD said.
“His strong finance and leadership capabilities position him well to serve as interim CFO as we continue to deliver on our strategic goals,“ CEO Tom Polen said in a statement.
BD said DelOrefice’s departure is not due to any disagreement with the company about financial statements, financial reporting, operations, policies or practices.
Fourth-quarter results
BD also announced preliminary fiscal fourth-quarter revenue of about $5.9 billion, up 8.3% year over year. For fiscal year 2025, BD reported preliminary revenue of about $21.8 billion, up 8.2%.
Stifel analysts, in a note Wednesday, called the fourth-quarter results “disappointing” and below analysts’ consensus expectations.
Polen said the “dynamic macro environment” had a greater impact in the quarter than anticipated, particularly in vaccines and academic and government research, while growth was strong in the company’s interventional, patient monitoring and medication delivery businesses.
BD is planning to separate its biosciences and diagnostics business from the rest of the company. Waters and the BD business will combine in a deal valued at about $17.5 billion, the companies said in July.
BD plans to discuss its fiscal fourth-quarter and full-year earnings on a Nov. 6 earnings call.
